Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STP 705

Next Previous
X
Search
Drug Profile

STP 705

Alternative Names: Anti-fibrosis RNA interference therapeutic - Sirnaomic; Cotsiranib; STP-705; STP-705LU; STP-705LV; STP705L

Latest Information Update: 26 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Developer Sirnaomics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Immunotherapies; Skin disorder therapies; Small interfering RNA; Stem cell therapies
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cyclooxygenase 2 expression inhibitors; RNA interference; Transforming growth factor beta1 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Keloids; Primary sclerosing cholangitis; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Bowen's disease; Hypertrophic scars; Keloids
  • Phase I Cholangiocarcinoma; Liver cancer; Obesity
  • No development reported Bladder cancer

Most Recent Events

  • 19 Sep 2024 Pharmacodynamics data from a preclinical studies in Obesity released by Sirnaomics
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Cholangiocarcinoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top